Drug discovery in Cytopathology

The rapid pace of drug discovery and drug development in Cytopathology, oncology, immunology and ophthalmology brings new challenges; the efficient and effective development of new targeted drugs will require more detailed molecular classifications of histologically homogeneous diseases that show heterogeneous clinical outcomes. Drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances. Enhanced accuracy of cell imaging and analysis systems helps in reducing the time and costs involved in the drug discovery process. This is a major factor driving the growth of the cell analysis market. Furthermore, the market is witnessing significant technological innovations and continuous improvements in cell analysis instruments and consumables for applications such as cell identification, cell proliferation, and target toxicity studies. This is another factor propelling the growth of this market. Corporate and government support for the growth of innovative technologies and rising demand for outsourcing of drug discovery services, especially in the Asia-Pacific region, are also the major reasons for the high-growth of this market. Based on cell analysis products, the consumables market commanded the largest share of ~65.5% in 2013. However, the cell analysis instruments market is poised to grow at the highest CAGR from 2013 to 2018.
  • Cytopathology in future medicine
  • Advancements in diagnosis pathology
  • Drug Therapies related to Cytopathology
  • DNA microarrays for assay development
  • Pharmacogenomics & Pharmacokinetics
  • Molecular Modelling
  • Drug targeting & Cytopathology in drug development

Related Conference of Drug discovery in Cytopathology

November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE
April 19-20, 2018

7th World Congress on Immunology

Amsterdam, Netherlands
May 28-29, 2018

World Congress on Allergy and Immunotherapy

Osaka, Japan

9th European Immunology Conference

June 14-16, 2018 Rome, Italy
July 05-07, 2018

EuroSciCon Conference on Immunology Conference 2018

Vienna, Austria
July 12-13, 2018

5th International Conference on Parasitology

Paris, France

Drug discovery in Cytopathology Conference Speakers

Recommended Sessions

Related Journals

Are you interested in